STCube announces clinical and preclinical results of 안전한 바카라 사이트-targeting immune checkpoint inhibitor ‘nelmastobart’
[by Ji, Yong Jun] STCube revealed on April 30 that it presented its next-generation immunotherapy treatment strategy and corresponding clinical research findings targeting the ‘BTN1A1-YAP1’ axis at the ‘American Association for Cancer Research Annual Meeting (AACR 2025),’ held in Chicago, USA.
The company emphasized the significance of its presentation, noting that it introduces a potential novel immunotherapeutic mechanism capable of addressing the limitations of current immunotherapy drugs. STCube further reported that it clarified the interaction mechanism between 안전한 바카라 사이트 and YAP1 and provided empirical evidence that a therapeutic strategy targeting this axis may help overcome anticancer resistance and improve treatment efficacy in colorectal and lung cancers.
In the first poster presentation, titled ‘Expression of 안전한 바카라 사이트 and YAP1 as Biomarkers of Colon Cancer and Results of Phase 1b Clinical Trial of nelmastobart,’ STCube analyzed the correlation between 안전한 바카라 사이트 expression levels and clinical outcomes based on data from a Phase 1b clinical trial involving patients with metastatic colorectal cancer. This investigator-initiated Phase 1b/2 clinical trial is designed to assess the efficacy and safety of a combination therapy of 'nelmastobart and capecitabine' as a third-line or higher treatment option. In the Phase 1b clinical trial, 12 patients with microsatellite stable (MSS) colorectal cancer were enrolled for seven months, and among them, two patients achieved partial remission (PR), while the remaining ten maintained stable disease (SD), yielding an objective response rate (ORR) of 17% and a disease control rate (DCR) of 100%. Subsequently, a Phase 2 trial involving 39 patients treated with nelmastobart 800 mg/m2 and capecitabine 1000 mg/ m2 was initiated and is currently in the follow-up observation stage.
Upon classifying seven patients from the phase 1b clinical trial based on clinical responses (PR, SD, SD→PD), the nelmastobart combination therapy demonstrated a notable survival benefit in patients with high 안전한 바카라 사이트 expression. Specifically, the ‘partial response (PR) group’ exhibited markedly higher 안전한 바카라 사이트 expression levels compared to the ‘stable lesion (SD)’ and ‘stable lesion followed by disease progression (SD→PD)’ groups, with a downward trend in 안전한 바카라 사이트 expression observed as clinical progression advanced.
“A measurable reduction in tumor size was observed even among patients with SD, with around 45% of all participants in the Phase 1b clinical trial exhibiting a clinically meaningful treatment response,” expressed Stephen Sunghan Yoo, Chief Scientific Officer (CSO) of STCube. “Patients with high YAP1 expression, who made up 50% of the study population, demonstrated a strong correlation with 안전한 바카라 사이트 positivity and experienced improved progression-free survival (PFS) outcomes compared to those with low YAP1 expression.”
“These findings represent preliminary clinical evidence supporting the potential of a precision medicine approach based on biomarker stratification ahead of full-scale colorectal cancer trials,” Yoo further commented. “Through OPAL (multiple immunofluorescence staining) analysis, we not only visually confirmed the high co-expression of 안전한 바카라 사이트 and YAP1 in colorectal cancer, but also demonstrated that 안전한 바카라 사이트 plays a central role in a complex resistance mechanism by interacting with YAP1, a key modulator of the Hippo signaling pathway implicated in tumor proliferation, immune evasion, and drug resistance.”
In the second poster presentation, titled ‘Therapeutic Targeting of the 안전한 바카라 사이트 Pathway as a Novel Mechanism of Cancer Immune Evasion,’ the STCube research team elucidated the functional interplay between BTN1A1 and YAP1 in colorectal and lung cancer cell lines using 3D spheroid models. The study demonstrated that the co-expression of these two proteins constitutes a key mechanism of resistance to anticancer therapies and proposed a novel dual-target therapeutic approach that inhibits this pathway through BTN1A1.
Results from the 3D spheroid experiments, stratified by YAP1 expression levels, demonstrated that nelmastobart exhibited strong synergistic antitumor effects when combined with the existing anticancer drugs TAS-102 (colon cancer) and docetaxel (lung cancer). Notably, therapeutic efficacy was observed in the resistant model characterized by YAP1 overexpression. According to the company, these findings validate a complex mechanism of action in which YAP1-associated drug resistance is significantly reduced through 안전한 바카라 사이트 inhibition while concurrently activating a T cell-medicated immune response.
“This presentation indicates that 안전한 바카라 사이트 is more than just a novel immune checkpoint protein, it represents a critical therapeutic target and complex biomarker capable of simultaneously modulating cancer immune evasion and anticancer resistance,” Yoo stated. “By validating the therapeutic potential of targeting 안전한 바카라 사이트 through both clinical data and spheroid models, we have underscored the promising outlook and competitive edge of our clinical development strategy for colorectal and lung cancer,” he added.